Regimen Reference Order – MELA – cobimetinib + vemURAFenib

ARIA: CUTA - [cobimetinib + vemURAFenib]

Planned Course: **Until disease progression or unacceptable toxicity (1 cycle = 28 days)**
Indication for Use: **Melanoma Advanced/Metastatic**

Proceed with treatment if:

ANC equal to or greater than 1 x 10^9/L AND Platelets equal to or greater than 100 x 10^9/L

- **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Treatment Regimen – MELA – cobimetinib + vemURAFenib

Drug	Dose	CCMB Administration Guideline
cobimetinib	60 mg (three 20 mg tablets)	Orally once daily on Days 1 to 21 Swallow whole. Do not chew or crush
vemURAFenib	960 mg (four 240 mg tablets)	Orally twice daily on Days 1 to 28 Swallow whole. Do not chew or crush

cobimetinib (Cotellic®) available dosage strength: 20 mg tablet
Classification: Cytotoxic, Hazardous

vemURAFenib (Zelboraf®) available dosage strength: 240 mg tablet
Classification: Cytotoxic, Hazardous

REQUIRED MONITORING

Baseline

- CBC and differential, LFTs, electrolytes, urea, creatinine
- ECG and MUGA or Echocardiogram

Prior to each cycle

- CBC and differential, LFTs, electrolytes, urea, creatinine

Other

- Consideration of regular ECG and MUGA/Echocardiograms during therapy at the discretion of physician
- Ocular and dermatological assessment as clinically indicated

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
Not Applicable		

INSTRUCTIONS FOR PATIENT

- Advise patient about photosensitivity precautions
- Patient should report any eye problems, rash and bleeding

ADDITIONAL INFORMATION

- cobimetinib and vemURAFenib will be dispensed at CancerCare Manitoba Pharmacy
- cobimetinib can rarely cause rhabdomyolysis